Business Context and Reporting Period
Company: Bionano Genomics, Inc. (BNGO)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Bionano provides genome analysis solutions, primarily Optical Genome Mapping (OGM) systems (Saphyr and Stratys), nucleic acid purification systems (Ionic), and software (VIA). The company also offers diagnostic testing services through its subsidiary, Bionano Laboratories. The company is an early commercial-stage entity focused on research use only (RUO) applications, though it seeks reimbursement for clinical diagnostic uses.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $28.5 million | $30.8 million |
| Net Loss | $(26.4) million | $(112.0) million |
| Cash Used in Operating Activities | $(16.3) million | $(68.9) million |
| Cash and Cash Equivalents (Dec 31, 2025) | $3.0 million | $9.2 million |
| Short-Term Investments (Dec 31, 2025) | $16.3 million | $0.3 million |
| Restricted Cash/Investments (Dec 31, 2025) | $10.3 million | $11.4 million |
| Convertible Debentures Outstanding (Principal) | $10.3 million | $15.5 million |
| Accumulated Deficit | $(719.6) million | $(693.2) million |
Installed Base: 387 OGM systems as of December 31, 2025 (up 4.3% from 371 in 2024).
Flowcells Sold: 30,171 in 2025 (down 0.4% from 30,307 in 2024).
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 7% to $28.5 million, driven primarily by a 53% drop in service and other revenue due to the phase-out of certain clinical testing services (neurodevelopmental disorders and hematologic malignancies) in 2024 and 2025. Instrument revenue fell 21% due to a strategic shift away from new placements toward maximizing utilization of the existing installed base.
- Improved Profitability Metrics: Net loss narrowed significantly by 76% to $26.4 million. This improvement was driven by a 55% reduction in operating expenses, largely due to headcount reductions and the absence of $19.7 million in intangible asset impairments and $8.0 million in restructuring costs recorded in 2024.
- Gross Margin Expansion: Product gross margin improved from a negative 5% in 2024 to 46% in 2025. This was primarily due to the non-recurrence of $9.8 million in inventory-related charges (excess/obsolete inventory and underutilized reagent rentals) recorded in 2024.
- Financing Activity: The company raised approximately $31.1 million in gross proceeds through registered direct offerings and at-the-market (ATM) sales in 2025. It also redeemed the High Trail Notes in May 2024 and issued JGB Convertible Debentures.
Guidance, Outlook, Risks, and Contingencies
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern within 12 months of the report issuance. The company expects to incur continued operating losses and requires additional capital to fund operations into the first quarter of 2027. Without additional financing, the company may need to curtail operations or seek bankruptcy protection.
- Strategic Shift: The company is focusing on driving utilization of its existing installed base of OGM systems rather than prioritizing new instrument placements. This strategy is expected to slow instrument revenue growth.
- Reimbursement Progress: The American Medical Association (AMA) established Category I CPT codes for OGM in constitutional genetic disorders (effective Jan 1, 2026) and increased payment determinations for hematologic malignancies. This is a key component for future commercial adoption.
- Debt Obligations: The company has $10.3 million in principal outstanding under JGB Convertible Debentures. Terms require monthly redemptions (up to $0.5 million through July 2025, then $1.4 million). Failure to meet these obligations could trigger a default.
- Regulatory Risks: Products are currently labeled "Research Use Only" (RUO). If the FDA determines these are medical devices or ends enforcement discretion for Laboratory Developed Tests (LDTs), the company may need to cease sales or obtain costly regulatory approvals.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of current cash ($3.0M) and short-term investments ($16.3M) against the $10.3M restricted cash requirement and monthly debt redemption obligations.
- Capital Raising Status: Confirm if the company has secured the "additional capital" required to fund operations beyond Q1 2027, as explicitly stated as a necessity in the filing.
- Debt Covenant Compliance: Monitor the company's ability to meet the monthly redemption payments on the JGB Debentures and maintain the required restricted cash balance.
- Revenue Mix Sustainability: Assess whether the 46% product gross margin is sustainable without the one-time benefit of avoiding 2024 inventory write-offs.
- Reimbursement Impact: Track the actual uptake of the new Category I CPT codes effective January 2026 to determine if they will drive the anticipated increase in clinical adoption.